Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardiovascular benefits in diabetic populations, yet evidence in non-diabetic obesity remains limited. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.